Sign in

Micheal Almisry Sonntag

Research Analyst at Leerink Partners

Michael Almisry Sonntag is an analyst at Leerink Partners LLC, specializing in healthcare and life sciences research. He covers leading healthcare companies, leveraging a data-driven approach to provide timely and high-conviction investment recommendations, although specific platform performance metrics such as TipRanks success rate and average returns are not publicly available. Sonntag began his career as a registered broker and joined Leerink Partners in recent years, with a verified history and credentials listed on FINRA BrokerCheck. He holds FINRA securities licenses and maintains a clean professional record with focus on providing actionable insights for institutional clients.

Micheal Almisry Sonntag's questions to AbCellera Biologics (ABCL) leadership

Question · Q4 2024

Micheal Almisry Sonntag from Leerink Partners inquired about the drivers behind initiating new internal programs, particularly the focus on ion channels and GPCRs, and whether program initiation activity in 2025 would be similar to 2024.

Answer

CEO Carl L. Hansen outlined their program selection framework, which prioritizes high conviction in the science, large unmet need, differentiation, and a clear, efficient development path. He explained the focus on ion channels and GPCRs is due to many validated targets in these classes where an antibody can offer differentiation. He noted this is an area of competitive strength for AbCellera, representing about 50% of the pipeline, a proportion he expects to remain roughly constant.

Ask follow-up questions

Fintool

Fintool can predict AbCellera Biologics logo ABCL's earnings beat/miss a week before the call

Let Fintool AI Agent track Micheal Almisry Sonntag for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free